Target price | JPY342.86 |
Course | JPY378.00 |
Deviation |
9.30%
register free of charge
|
Number of estimates | 7 |
7 Analysts have issued a price target Sumitomo Dainippon Pharma 2025 .
The average Sumitomo Dainippon Pharma target price is JPY342.86.
This is
9.30%
register free of charge
JPY430.00
13.76%
register free of charge
JPY190.00
49.74%
register free of charge
|
|
A rating was issued by 7 analysts: 0 Analysts recommend Sumitomo Dainippon Pharma to buy, 4 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst estimates: Analysts believe that the Sumitomo Dainippon Pharma share has an average upside potential 2025 of
9.30%
register free of charge
|
Mar '24 |
2025 Forecast |
|
---|---|---|
Turnover Billion JPY | 314.56 | 341.29 |
43.38% | 8.50% | |
EBITDA margin | 11.54% | 7.20% |
22.16% | 37.59% | |
Net margin | -100.13% | -6.52% |
646.55% | 93.49% |
7 Analysts have issued a sales forecast Sumitomo Dainippon Pharma 2025 . The average Sumitomo Dainippon Pharma sales estimate is
This results in the following potential growth figures:
6 Analysts have issued an Sumitomo Dainippon Pharma EBITDA forecast 2025. The average Sumitomo Dainippon Pharma EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
3 Sumitomo Dainippon Pharma Analysts have issued a net profit forecast 2025. The average Sumitomo Dainippon Pharma net profit estimate is
This results in the following potential growth figures and future net margins:
Mar '24 |
2025 Forecast |
|
---|---|---|
Earnings per share JPY | -792.79 | -55.97 |
322.71% | 92.94% | |
P/E ratio | negative | |
EV/Sales | 1.62 |
3 Analysts have issued a Sumitomo Dainippon Pharma forecast for earnings per share. The average Sumitomo Dainippon Pharma <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2025, the Sumitomo Dainippon Pharma share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
Sumitomo Dainippon Pharma...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.